The Motley Fool
Neutral
8/7 7:28 PM
Pfizer's Next Weight-Loss Weapon: How Berobenatide Stacks Up Against Novo Nordisk's Wegovy and Eli Lilly's Zepbound
Pfizer's berobenatide appears to be a promising candidate that could challenge Wegovy and Zepbound. There are several other reasons to consider the stock, despite the potential headwinds ahead.
Finbold
Positive
8/7 2:40 PM
Monster insider trading alert for Pfizer stock
As Pfizer Inc. (NYSE: PFE) stock gained over 5% this week fueled by its strong second quarter 2026 earnings report, Finbold has observed its increased insider trading.
24/7 Wall Street
Neutral
8/6 4:00 PM
After Q2 Earnings, Is Pfizer or Merck the Smarter Dividend Play?
Pfizer (NYSE:PFE | PFE Price Prediction) and Merck (NYSE:MRK) refreshed the dividend debate with their latest quarterly reports.
Seeking Alpha
Positive
8/6 1:59 PM
Pfizer: Q2 Strength Overshadows Obesity Setbacks
Pfizer shares edged higher after Q2 earnings, shrugging off criticism over the discontinuation of two obesity drug candidates, MET-224o and PF-07976016. PFE highlighted Metsera's rapid progress and plans to strategically deploy its remaining $6 billion-$7 billion toward bolt-on opportunities in oncology, IMIDs, and obesity. In Q2, sales of the tafamidis franchise were $1.76 billion, up 10% QoQ.
Zacks Investment Research
Positive
8/5 3:02 PM
Pfizer Q2 Earnings Call Highlights Non-COVID Growth and Cost Cuts
PFE raises its 2026 revenue outlook as non-COVID growth, deeper cost cuts and pipeline catalysts offset weaker COVID demand.
MarketBeat
Neutral
8/5 12:04 PM
Pfizer Q2 Earnings Call Highlights
Pfizer NYSE: PFE reported second-quarter 2026 revenue of $15 billion and adjusted diluted earnings per share of $0.77, with management saying both measures exceeded its internal expectations. Revenue increased 1% operationally from a year earlier, while revenue excluding COVID-19 products rose 5% operationally.
Seeking Alpha
Neutral
8/4 8:20 PM
Pfizer Inc. (PFE) Q2 2026 Earnings Call Transcript
Pfizer Inc. (PFE) Q2 2026 Earnings Call Transcript
Zacks Investment Research
Positive
8/4 4:46 PM
PFE Q2 Earnings Top, 2026 Sales View Tweaked, COVID Forecast Cut
Pfizer beats Q2 earnings and revenue estimates, raises the low end of its 2026 sales outlook, but lowers expectations for COVID product revenues.
Zacks Investment Research
Neutral
8/4 2:31 PM
Compared to Estimates, Pfizer (PFE) Q2 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Pfizer (PFE) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Proactive Investors
Positive
8/4 2:28 PM
Pfizer raises revenue outlook after quarterly earnings top estimates
Pfizer Inc (NYSE:PFE, XETRA:PFE) beat Wall Street expectations for its second-quarter 2026 results and raised the midpoint of its full-year revenue guidance, as growth from launched and acquired products helped offset declines in its COVID-19 portfolio. The pharmaceutical company reported adjusted earnings of $0.77 per share for the quarter, above the $0.68 expected by analysts.
52W Range
$23.58 - $28.75
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
